Avalo Therapeutics
AVTX
61 hedge funds and large institutions have $180M invested in Avalo Therapeutics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 6 reducing their positions, and 6 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 6
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
37% more capital invested
Capital invested by funds: $131M → $180M (+$48.9M)
15% more funds holding
Funds holding: 53 → 61 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
44% less call options, than puts
Call options by funds: $84K | Put options by funds: $151K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$8.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.04M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.66M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.29M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$1.23M |
| 2 |
MWM
Minot Wealth Management
Westwood,
Massachusetts
|
-$170K |
| 3 |
Morgan Stanley
New York
|
-$170K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$66.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$47.2K |
AVTX Hedge Fund Activity: Q1 2021 in Review
61 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2021, worth a combined $180M — up 37% from $131M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AVTX positions and 6 closed out — a net gain of 8 holders — while 28 added to existing stakes and 6 trimmed.
The largest buyer was Armistice Capital, adding an estimated $8.2M. The largest seller was Sio Capital Management, cutting an estimated $1.23M.
- 61 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2021, up from 53 in Q4 2020.
- Funds reported $180M of Avalo Therapeutics stock for Q1 2021, up 37% quarter-over-quarter.
- 14 funds opened new Avalo Therapeutics positions in Q1 2021 and 6 closed out, a net change of +8 holders.
- The largest Avalo Therapeutics buyer in Q1 2021 was Armistice Capital, an estimated $8.2M added.
- The largest Avalo Therapeutics seller in Q1 2021 was Sio Capital Management, an estimated $1.23M sold.
Based on aggregated 13F filings for Q1 2021.